EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover Study

Reindert F Oostveen iD, Yannick Kaiser, Merel L Hartgers, Emma C E Meessen, Aldo Grefhorst iD, G Kees Hovingh iD, Folkert Kuipers iD, Erik S G Stroes iD, Albert K Groen iD, Laurens F Reeskamp iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.035259 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Reindert F Oostveen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam Cardiovascular Sciences Amsterdam UMC, University of Amsterdam The Netherlands. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Cross-Over Studies, Feces, Cholesterol, LDL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The trans intestinal cholesterol excretion (TICE) pathway is a potential therapeutic target to reduce plasma low‐density lipoprotein (LDL) cholesterol levels. TICE encompasses the direct excretion of cholesterol by enterocytes into feces. In mice, TICE has been shown to be stimulated by a hydrophilic bile acid pool, resulting in increased fecal neutral sterol loss and reduced plasma cholesterol levels. We investigated whether treatment with a hydrophilic bile acid, ursodeoxycholic acid (UDCA), would increase fecal neutral sterols in humans as a proxy for TICE. Methods and Results We performed a randomized, double‐blind, placebo‐controlled, cross‐over trial in 20 male participants aged >18 years, with plasma LDL cholesterol levels ≥2.6 mmol/L. After a run‐in period of ezetimibe 20 mg once daily for 3 weeks, patients were randomized to UDCA 600 mg or placebo orally once daily for 2 weeks. After a 3 week washout, patients underwent the alternate treatment. At baseline, mean (SD) age, body mass index, and plasma LDL cholesterol were 59±11.3 years, 26.4±3.1 kg/m 2 , and 3.9±0.8 mmol/L, respectively. After UDCA treatment, the plasma bile acid hydrophobicity index was reduced compared with placebo (−118.7% versus +2.3%, P 2.6 mmol/L but did not result in increased fecal neutral sterols or decreased LDL cholesterol. This suggests that TICE is not stimulated by an increase in the hydrophilicity of the bile acid pool in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidCross-Over StudiesFecesCholesterol, LDLHumansMaleMiddle AgedDouble-Blind MethodAnticholesteremic AgentsAgedEzetimibeCholesterolIntestinal EliminationTreatment Outcome

Stichwörter der Autor:innen

ezetimibelipidstrans intestinal cholesterol excretionursodeoxycholic acid

Substanzen

Ursodeoxycholic AcidCholesterol, LDLAnticholesteremic AgentsEzetimibeCholesterol

Autor:innen und Institutionen

  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences Amsterdam UMC, University of Amsterdam The Netherlands.
  • Department of Endocrinology and Metabolism Amsterdam UMC, University of Amsterdam The Netherlands.
  • Department of Experimental Vascular Medicine Amsterdam UMC, University of Amsterdam The Netherlands.
  • Department of Pediatrics University Medical Center Groningen, University of Groningen The Netherlands.
  • European Research Institute for the Biology of Ageing (ERIBA) University Medical Center Groningen, University of Groningen The Netherlands.

ORCID-Profile: Reindert F Oostveen, Aldo Grefhorst, G Kees Hovingh, Folkert Kuipers, Erik S G Stroes, Albert K Groen, Laurens F Reeskamp

Zitieren

APA

Oostveen, R. F., Kaiser, Y., Hartgers, M. L., Meessen, E. C. E., Grefhorst, A., Hovingh, G. K., Kuipers, F., Stroes, E. S. G., Groen, A. K., & Reeskamp, L. F. (2024). Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.035259

Vancouver

Oostveen RF, Kaiser Y, Hartgers ML, Meessen ECE, Grefhorst A, Hovingh GK, et al. Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover Study. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.035259

BibTeX
@article{Oostveen2024,
  author = {Oostveen, Reindert F and Kaiser, Yannick and Hartgers, Merel L and Meessen, Emma C E and Grefhorst, Aldo and Hovingh, G Kees and Kuipers, Folkert and Stroes, Erik S G and Groen, Albert K and Reeskamp, Laurens F},
  title = {Ursodeoxycholic Acid for Trans Intestinal Cholesterol Excretion Stimulation: A Randomized Placebo Controlled Crossover Study},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.035259}
}
Kostenlos starten →